Kenvue Inc. $KVUE Holdings Raised by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 22.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 173,078 shares of the company’s stock after buying an additional 32,022 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Kenvue were worth $2,984,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of KVUE. Elyxium Wealth LLC acquired a new position in shares of Kenvue in the fourth quarter worth $26,000. Physician Wealth Advisors Inc. boosted its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. MV Capital Management Inc. acquired a new stake in Kenvue during the fourth quarter valued at $28,000. Reflection Asset Management acquired a new stake in Kenvue during the fourth quarter valued at $32,000. Finally, SBI Securities Co. Ltd. grew its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on KVUE. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Barclays cut their price objective on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.33.

Kenvue Trading Down 1.4%

NYSE:KVUE opened at $17.86 on Tuesday. The company’s 50 day moving average is $17.54 and its 200-day moving average is $17.58. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $22.87. The firm has a market cap of $34.30 billion, a price-to-earnings ratio of 21.02, a P/E/G ratio of 1.37 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.24 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.59% of the company’s stock.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.